Lexeo Therapeutics rises after receiving fast track tag for gene therapy

Lexeo Therapeutics

16/04/2024 13:27

** Drug developer Lexeo Therapeutics'  LXEO.O  shares rise
5.8% to $12.79 premarket
    ** Company says U.S. FDA has granted "fast track"
designation for its experimental gene therapy LX2006 for the
treatment of Friedreich's ataxia (FA) cardiomyopathy
    ** Fast track status expedites the review of drug candidates
being developed to treat serious conditions
    ** LX2006 is designed to target the cardiac manifestations
of FA, which is a rare, inherited disorder that causes
progressive damage to the nervous system
    ** As of last close, stock down 9.9% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com))